Latest Hotspot

Sandoz Launches Tyruko®, a Unique Biosimilar for Multiple Sclerosis Treatment, in Germany

9 February 2024
3 min read

Sandoz, an internationally recognized pioneer in the production of generics and biosimilars, has revealed the introduction of its product, Tyruko® (natalizumab), in the German market starting February 1. Originating from the research and development efforts of Polpharma Biologics, Tyruko® stands out as the inaugural biosimilar on the market specifically formulated for the management of Relapsing-Remitting Multiple Sclerosis (RRMS).

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Tyruko® is recommended for sole use as a transformative treatment for adult individuals battling severe forms of RRMS. This usage is congruent with the prior authorization granted by the European Commission for the originator medicine, Tysabri®.

Rebecca Guntern, who leads the European division for Sandoz, commented, “Initiating treatment with transformative therapies early on can greatly influence the lives of those affected by multiple sclerosis, potentially curbing future physical impairments. Tyruko®, being the unique biosimilar of its kind, marks a pivotal point in extending the reach of efficacious and reliable treatments to individuals across Europe, particularly to those whose needs are most pressing.”

Currently, only about 20% of patients with MS in Europe have the opportunity to benefit from cutting-edge, highly potent DMTs. In Eastern Europe, the percentage is drastically lower, between 3% and 4%, indicating a pressing need to expand uninhibited access to these vital medications to delay irreversible neurological harm and halt the progression of the disease.

In 2019, Sandoz secured a comprehensive licensing deal with Polpharma Biologics for the global commercialization of a biosimilar natalizumab. As per the terms, Polpharma Biologics is tasked with the continued development, manufacturing, and provision of the active pharmaceutical ingredient. Sandoz, through an exclusive worldwide license, is authorized to market and disseminate the drug across international territories.

Sandoz pledges to facilitate access to essential biologic drugs for millions of patients at sustainable and economical prices, impacting diverse medical fields such as immunology, oncology, supportive care, endocrinology, and now includes neurology as well. It boasts a prominent global portfolio of nine biosimilars that have already hit the market, along with an additional 24 in the pipeline.

Since the introduction of its premier biosimilar in Europe back in 2006, Sandoz has consistently worked towards enhancing patient access to transformative drugs earlier, fostering economic healthcare solutions, and stimulating competitiveness that drives further medical advancements.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of February 7, 2024, there are 14 investigational drugs for the CD49d target, including 29 indications, 24 R&D institutions involved, with related clinical trials reaching 139, and as many as 5245 patents.

Natalizumab targets CD49d and is approved for the treatment of Crohn's disease and relapsing-remitting MS. The drug has received accelerated approval and orphan drug designation, reflecting its potential to address unmet medical needs. While Natalizumab has shown efficacy in clinical trials, it is important to consider the associated risks and carefully evaluate its use in patients.

图形用户界面, 文本, 应用程序

描述已自动生成

How to Effectively Search for Furosemide on Synapse
Drug Insights
2 min read
How to Effectively Search for Furosemide on Synapse
9 February 2024
Furosemide is a small molecule NKCC2 inhibitor drug, blocking the sodium-potassium-chloride co-transporter in the kidney's ascending loop of Henle.
Read →
J&J Seeks FDA Approval for DARZALEX FASPRO in Treating Newly Diagnosed Multiple Myeloma Cases
Latest Hotspot
4 min read
J&J Seeks FDA Approval for DARZALEX FASPRO in Treating Newly Diagnosed Multiple Myeloma Cases
9 February 2024
Johnson & Johnson has filed an additional request with the FDA for authorization of its DARZALEX FASPRO formula as a therapy option for newly identified multiple myeloma cases eligible for transplant.
Read →
Your Ultimate Guide to Finding Clonazepam on Synapse
Drug Insights
2 min read
Your Ultimate Guide to Finding Clonazepam on Synapse
9 February 2024
KLONOPIN (clonazepam) is a benzodiazepine medication that was first approved by the FDA in 1975 for the treatment of seizure disorders and panic disorder.
Read →
US and Japan Approve BMS's Breyanzi Filings for Recurrent Lymphomas
Latest Hotspot
3 min read
US and Japan Approve BMS's Breyanzi Filings for Recurrent Lymphomas
9 February 2024
U.S. and Japanese authorities have approved filings for Bristol Myers Squibb's Breyanzi, aimed at treating recurrent Follicular and Mantle Cell Lymphomas.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.